The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.
Varicella live vaccines contain an attenuated form of the varicella zoster virus. These vaccines help build immunity against varicella zoster virus as the infection can cause serious diseases such as chicken pox and herpes zoster. Immunization against these diseases is necessary as chicken pox can lead to serious complications such as bacterial infections of the skin and soft tissues in children.
Moreover, herpes zoster is another painful condition that is caused by the reactivation of the varicella zoster virus after primary infection. Therefore, immunization with varicella live vaccine serves as an effective method for prevention of these diseases. These vaccines are mainly of two types such as monovalent and combination. The monovalent vaccines contain a single strain of a single antigen such as varicella live vaccines, contain weakened strain of varicella zoster virus. However, the combination varicella vaccines contain multiple strains of infectious agents.
The factors that boost the growth of the varicella live vaccine market include surge in immunization programs across the globe. Moreover, rise in awareness related to the use of varicella live vaccines and surge in adoption of varicella vaccination worldwide also fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The global varicella live vaccine market is segmented based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization.
On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Product
o Monovalent Varicella Vaccine
o Combination Varicella Vaccine
• By Application
o Chickenpox immunization
o Herpes Zoster Immunization
o Mumps, Measles, Rubella and Varicella (MMRV) Immunization
• By Provider
o Public Provider
o Private Provider
• By Region
o North America
§ U.S.
§ Canada
§ Mexico
o Europe
§ Germany
§ France
§ UK
§ Italy
§ Spain
§ Rest of Europe
o Asia-Pacific
§ Japan
§ China
§ India
§ Australia
§ South Korea
§ Rest of Asia-Pacific
o LAMEA
§ Brazil
§ Saudi Arabia
§ South Africa
§ Rest of LAMEA
List of key players profiled in the report:
• Bio-Med Pvt. Limited
• Changchun BCHT Biotechnology Co. Ltd.
• Emcure Pharmaceuticals Limited
• GlaxoSmithKline plc
• Green Cross Holdings (GC Pharma)
• Merck & Co. Inc.
• Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
• Novo Medi Sciences Pvt. Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• VHB Life Sciences
• Wockhardt Ltd.
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter'S Five Forces Analysis
3.3.1. Bargaining Power of Buyers
3.3.2. Bargaining Power of Suppliers
3.3.3. Thereat of New Entrants
3.3.4. Threat of Substitutes
3.3.5. Intensity of Competitive Rivalry
3.4. Top Player Positioning, 2018
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Immunization Programs Across The Globe
3.5.1.2. Rise In Awareness Regarding Use of Varicella Live Vaccines
3.5.1.3. Increase In Adoption of Varicella Live Vaccines
3.5.2. Restraint
3.5.2.1. High Monetary Inputs Associated With The Production
3.5.3. Opportunity
3.5.3.1. High Growth Potential In Emerging Economies
3.5.4. Impact Analysis
Chapter 4: Varicella Live Vaccine Market, By Product
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Monovalent Varicella Vaccine
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Combination Varicella Vaccine
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
Chapter 5: Varicella Live Vaccine Market, By Application
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Chickenpox Immunization
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Herpes Zoster Immunization
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Mumps, Measles, Rubella & Varicella (Mmrv) Immunization
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
Chapter 6: Varicella Vaccine Market, By Provider
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Public
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Private
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
Chapter 7: Varicella Live Vaccine Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. Market Analysis By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Market Size And Forecast, By Product
7.2.2.1.2. U.S. Market Size And Forecast, By Application
7.2.2.1.3. U.S. Market Size And Forecast, By Provider
7.2.2.2. Canada
7.2.2.2.1. Canada Market Size And Forecast, By Product
7.2.2.2.2. Canada Market Size And Forecast, By Application
7.2.2.2.3. Canada Market Size And Forecast, By Provider
7.2.2.3. Mexico
7.2.2.3.1. Mexico Market Size And Forecast, By Product
7.2.2.3.2. Mexico Market Size And Forecast, By Application
7.2.2.3.3. Mexico Market Size And Forecast, By Provider
7.2.3. North America Market Size And Forecast, By Product
7.2.4. North America Market Size And Forecast, By Application
7.2.5. North America Market Size And Forecast, By Provider
7.3. Europe
7.3.1. Key Market Trends And Opportunities
7.3.2. Market Analysis By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Market Size And Forecast, By Product
7.3.2.1.2. Germany Market Size And Forecast, By Application
7.3.2.1.3. Germany Market Size And Forecast, By Provider
7.3.2.2. France
7.3.2.2.1. France Market Size And Forecast, By Product
7.3.2.2.2. France Market Size And Forecast, By Application
7.3.2.2.3. France Market Size And Forecast, By Provider
7.3.2.3. Uk
7.3.2.3.1. Uk Market Size And Forecast, By Product
7.3.2.3.2. Uk Market Size And Forecast, By Application
7.3.2.3.3. Uk Market Size And Forecast, By Provider
7.3.2.4. Italy
7.3.2.4.1. Italy Market Size And Forecast, By Product
7.3.2.4.2. Italy Market Size And Forecast, By Application
7.3.2.4.3. Italy Market Size And Forecast, By Provider
7.3.2.5. Spain
7.3.2.5.1. Spain Market Size And Forecast, By Product
7.3.2.5.2. Spain Market Size And Forecast, By Application
7.3.2.5.3. Spain Market Size And Forecast, By Provider
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Market Size And Forecast, By Product
7.3.2.6.2. Rest of Europe Market Size And Forecast, By Application
7.3.2.6.3. Rest of Europe Market Size And Forecast, By Provider
7.3.3. Europe Market Size And Forecast, By Product
7.3.4. Europe Market Size And Forecast, By Application
7.3.5. Europe Market Size And Forecast, By Provider
7.4. Asia-Pacific
7.4.1. Key Market Trends And Opportunities
7.4.2. Market Analysis By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Market Size And Forecast, By Product
7.4.2.1.2. Japan Market Size And Forecast, By Application
7.4.2.1.3. Japan Market Size And Forecast, By Provider
7.4.2.2. China
7.4.2.2.1. China Market Size And Forecast, By Product
7.4.2.2.2. China Market Size And Forecast, By Application
7.4.2.2.3. China Market Size And Forecast, By Provider
7.4.2.3. Australia
7.4.2.3.1. Australia Market Size And Forecast, By Product
7.4.2.3.2. Australia Market Size And Forecast, By Application
7.4.2.3.3. Australia Market Size And Forecast, By Provider
7.4.2.4. India
7.4.2.4.1. India Market Size And Forecast, By Product
7.4.2.4.2. India Market Size And Forecast, By Application
7.4.2.4.3. India Market Size And Forecast, By Provider
7.4.2.5. South Korea
7.4.2.5.1. South Korea Market Size And Forecast, By Product
7.4.2.5.2. South Korea Market Size And Forecast, By Application
7.4.2.5.3. South Korea Market Size And Forecast, By Provider
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Market Size And Forecast, By Product
7.4.2.6.2. Rest of Asia-Pacific Market Size And Forecast, By Application
7.4.2.6.3. Rest of Asia-Pacific Market Size And Forecast, By Provider
7.4.3. Asia-Pacific Market Size And Forecast, By Product
7.4.4. Asia-Pacific Market Size And Forecast, By Application
7.4.5. Asia-Pacific Market Size And Forecast, By Provider
7.5. Lamea
7.5.1. Key Market Trends And Opportunities
7.5.2. Market Analysis By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Market Size And Forecast, By Product
7.5.2.1.2. Brazil Market Size And Forecast, By Application
7.5.2.1.3. Brazil Market Size And Forecast, By Provider
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Market Size And Forecast, By Product
7.5.2.2.2. Saudi Arabia Market Size And Forecast, By Application
7.5.2.2.3. Saudi Arabia Market Size And Forecast, By Provider
7.5.2.3. South Africa
7.5.2.3.1. South Africa Market Size And Forecast, By Product
7.5.2.3.2. South Africa Market Size And Forecast, By Application
7.5.2.3.3. South Africa Market Size And Forecast, By Provider
7.5.2.4. Rest of Lamea
7.5.2.4.1. Rest of Lamea Market Size And Forecast, By Product
7.5.2.4.2. Rest of Lamea Market Size And Forecast, By Application
7.5.2.4.3. Rest of Lamea Market Size And Forecast, By Provider
7.5.3. Lamea Market Size And Forecast, By Product
7.5.4. Lamea Market Size And Forecast, By Application
7.5.5. Lamea Market Size And Forecast, By Provider
Chapter 8: Company Profiles
8.1. Bio-Med Pvt. Limited
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.1.4. Key Strategic Moves And Developments
8.2. Changchun Bcht Biotechnology Co. Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.3. Emcure Pharmaceuticals Limited (Zuventus Healthcare Ltd.)
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Product Portfolio
8.4. Glaxosmithkline Plc
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Green Cross Holdings (Gc Pharma)
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Product Portfolio
8.5.4. Business Performance
8.6. Merck & Co. Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves And Developments
8.8. Novo Medi Sciences Pvt. Ltd.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Takeda Pharmaceutical Company Limited
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
